Associations of insulin-like growth factor binding protein-3 gene polymorphisms with IGF-I activity and lipid parameters in adolescents

International Journal of Obesity

Volumn 33, Issue 12, 2009, Pages 1446-1453

  Mong, J L Y ^a   Ng, M C Y ^a   Guldan, G S ^a   Tam, C H T ^a   Lee, H M ^a   Ma, R C W ^a   So, W Y ^a   Wong, G W K ^a   Kong, A P S ^a   Chan, J C N ^a   Waye, M M Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adolescents; IGF I activity; Insulin like growth factor binding protein 3 (IGFBP 3); Lipids; Single nucleotide polymorphisms (SNPs)

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; LIPID;

ADOLESCENT; ALLELE; ARTICLE; BLOOD PRESSURE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DNA FLANKING REGION; FACTORIAL ANALYSIS; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; GENETICS; GENOTYPE; HONG KONG; METABOLISM;

ADOLESCENT; BODY COMPOSITION; FEMALE; GENOTYPE; HONG KONG; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MALE; OBESITY; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 72049092015     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.186     Document Type: Article

References (40)

1. Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005; 111: 1999-2012.
2. Ozaki R, Qiao Q, Wong GW, Chan MH, So WY, Tong PC et al. Overweight, family history of diabetes and attending schools of lower academic grading are independent predictors for metabolic syndrome in Hong Kong Chinese adolescents. Arch Dis Child 2007; 92: 224-228.
3. Steinberger J, Moran A, Hong CP, Jacobs Jr DR, Sinaiko AR. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J Pediatr 2001; 138: 469-473.
4. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
5. Li JK, Ng MC, So WY, Chiu CK, Ozaki R, Tong PC et al. Phenotypic and genetic clustering of diabetes and metabolic syndrome in Chinese families with type 2 diabetes mellitus. Diabetes Metab Res Rev 2006; 22: 46-52.
6. Walley AJ, Blakemore AI, Froguel P. Genetics of obesity and the prediction of risk for health. Hum Mol Genet 2006; 15 (Spec No 2): R124-R130.
7. Lee ZS, Chan JC, Yeung VT, Chow CC, Lau MS, Ko GT et al. Plasma insulin, growth hormone, cortisol, and central obesity among young Chinese type 2 diabetic patients. Diabetes Care 1999; 22: 1450-1457.
8. Tong PC, Ho CS, Yeung VT, Ng MC, So WY, Ozaki R et al. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 6418-6423.
9. Nam SY, Kim KR, Cha BS, Song YD, Lim SK, Lee HC et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2001; 25: 1101-1107.
10. Kong AP, Chan NN, Chan JC. The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr Diabetes Rev 2006; 2: 397-407.
11. Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005; 26: 114-146.
12. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.
13. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994; 42: 140-144.
14. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
15. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L, Brismar K. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 2007; 30: 2343-2348.
16. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007; 56: 285-294.
17. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol 2007; 166: 518-526.
18. Mauras N, Blizzard RM, Link K, Johnson ML, Rogol AD, Veldhuis JD. Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon. J Clin Endocrinol Metab 1987; 64: 596-601.
19. Ng VW, Kong AP, Choi KC, Ozaki R, Wong GW, So WY et al. BMI and waist circumference in predicting cardiovascular risk factor clustering in Chinese adolescents. Obesity (Silver Spring) 2007; 15: 494-503.
20. Kong AP, Wong GW, Choi KC, Ho CS, Chan MH, Lam CW et al. Reference values for serum levels of insulin-like growth factor (IGF-1) and IGF-binding protein 3 (IGFBP-3) and their ratio in Chinese adolescents. Clin Biochem 2007; 40: 1093-1099.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-150.
23. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 2-19.
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
25. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63: 8912-8921.
26. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63: 627-635.
27. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353.
28. Hochberg Z, Hertz P, Maor G, Oiknine J, Aviram M. Growth hormone and insulin-like growth factor-I increase macrophage uptake and degradation of low density lipoprotein. Endocrinology 1992; 131: 430-435.
29. Ottosson M, Vikman-Adolfsson K, Enerback S, Elander A, Bjorntorp P, Eden S. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1995; 80: 936-941.
30. Yang X, So WY, Ko GT, Ma RC, Kong AP, Chow CC et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008; 179: 427-437.
31. Paquette J, Bessette B, Ledru E, Deal C. Identification of upstream stimulatory factor binding sites in the human IGFBP3 promoter and potential implication of adjacent single-nucleotide polymorphisms and responsiveness to insulin. Endocrinology 2007; 148: 6007-6018.
32. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36: 371-376.
33. Ng MC, Miyake K, So WY, Poon EW, Lam VK, Li JK et al. The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 2005; 48: 2018-2024.
34. Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 1997; 216: 319-357.
35. Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992; 74: 1355-1360.
36. Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997; 21: 355-359.
37. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001; 44: 333-339.
38. Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002; 51: 2629-2636.
39. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 939-944.
40. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004; 89: 114-120